LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC) (IMUC), a biotechnology company, announced today that it has elected James G. Bender, Ph.D., M.P.H., to the position of vice president, clinical development. Dr. Bender joins the company from biopharmaceutical company IDM Pharma and brings more than 20 years of clinical development experience to IMUC, including experience in stem cell research and development. Dr. Bender also has significant experience in guiding product candidates through their regulatory pathways at the U.S. Food and Drug Administration (FDA) as well as extensive internal management expertise, having managed large teams of up to 20 scientists.
